1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Human Insulin Market - Drugs , Type , Brands , Delivery Devices , Applications  - Forecasts to 2020

Human Insulin Market: Forecasts until 2020

  • January 2016
  • 183 pages
  • ID: 3552632
In this report:
In 2015, the insulin analogs & biosimilars segment is expected to account for the largest share of ##.##% of the human insulin drugs market in the U.S. This segment is poised to reach USD ##,##.## million by 2020 from USD ##,##.## million in 2015, growing at a CAGR of ##.##% during the forecast period.


Table of Contents

Search Inside

The overall human insulin market is poised to reach ~USD 39.13 billion by 2020 increasing at a compound annual growth rate (CAGR) of 8.10 percent between 2015 and 2022. North America (NA) is forecasted to hold the most important share of the overall human insulin market in 2015. Market increase of human insulin products is being propelled by increasing diabetes patient population, growing population exposure to main risk factors leading to diabetes, growing market demand for human insulin analogs, technological improvements in the field of human insulin delivery devices, and favorable medical reimbursements. Nevertheless, stringent regulatory requirements for product approval are selecting the rise of human insulin market. Additionally, high product manufacturing costs is posing significant challenges for industry growth during the estimate period.

In this industry report, the overall human insulin market is broken down on the basis of basis of products (human insulin biologics, insulin analogs & biosimilars, and delivery devices), drug type (rapid-acting, intermediate-acting, long-acting, short-acting, and premixed), drug brand (Lantus, NovoRapid/Novolog, Humalog, Humulin, Insuman, Actrapid, Insulatard, Mixtard, and Other Biosimilar Brands), delivery devices [insulin pens, pen needles, and conventional syringes], and applications.

Human insulin drugs segment is forecasted to account for the larger share of the overall human insulin market in 2015, succeeded by insulin delivery devices. Significant demand rise for human insulin drugs during the upcoming five years is owing to Elements such as rising market accessibility of generic human insulin products global, increasing government initiatives to support the development and commercialization of effective biosimilars, increasing R&D for drug discovery & development, and growing proportion of aging population in developed countries.

Geographically, North America continent (comprising the U.S.A and Canada (CA)) is anticipated to command the biggest share of the overall human insulin market in 2015, succeeded by Europe (EU). Asia Pacific (APAC) is also poised to grow at the highest compound annual growth rate (CAGR) during the outlook period, owing to Elements such as increasing diabetes prevalence in Asia-Pac, strengthening distribution networks of overall product manufacturers in the territory, evolving regulatory framework for marketing approvals & medical reimbursements, and increasing public awareness related to benefits suggested by human insulin in diabetes treatment.

The overall human insulin market is highly competitive, with different overall as well as local actors. In 2014, the overall human insulin devices market was dominated by Sanofi, Novo Nordisk A/S, and Eli Lilly and Organization, which together accounted for ~89.0% of the human insulin market. Geographic expansion, latest product launches, strategic agreements, collaborations, alliances, awareness campaigns, and offering research fund & grants are the main strategies approved by most market actors to accomplish increase in the overall human insulin market.

Why Purchasing This Study Can Help You:

From an insight prospect, this market research has emphasized several levels of review of the best ten market actors and company descriptions, which together comprise and examine the basic overviews on the competitive landscape, coming out and high-growth segments of the human insulin market, and high-growth areas and their respective drivers, market restraints, opportunities, and alternatives.

The market research will increase both established firms as well as new entrants/smaller companies to measure the pulse of the sector, which in turn help companies to collect higher market share. Companies obtaining the industry report could use any one or an aggregation of the below-mentioned five strategies (business entry, product improvement/innovative projects, industry development, industry diversification, and opposing assessment) for strengthening their market shares.

This study furnishes highlights on the following points:

-Market Penetration: Exhaustive information on the human insulin products provided by the most important 10 market actors in the overall market. The analysis examines the human insulin market by product, drug type, drug brand, delivery devices, and applications across top geographic regions

-Product Development/Innovative products: In-depth understanding on upcoming human insulin products, product pipeline, analysis and growth activities, and recent product launches in the sector

-Market Development: Highlighted information on profitable emerging sectors. The market research examines the industries for different human insulin products across main geographic regions

-Market Diversification: Complete information about recent products, untapped areas, recent evolutions, and market investments in the overall human insulin market

-Competitive Assessment: Detailed assessment of market shares, strategies, products, distribution networks, and manufacturing competences of key players in the overall human insulin market

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Nicolas helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Artificial Pancreas - Medical Devices Pipeline Assessment, 2018

Artificial Pancreas - Medical Devices Pipeline Assessment, 2018

  • $ 4000
  • Industry report
  • July 2018
  • by GlobalData

Artificial Pancreas - Medical Devices Pipeline Assessment, 2018SummaryGlobalData’s Medical Devices sector report, “Artificial Pancreas - Medical Devices Pipeline Assessment, 2018" provides an overview ...

Subcutaneous Biologics, Technologies and Drug Delivery Systems (2nd Edition), 2018-2030

Subcutaneous Biologics, Technologies and Drug Delivery Systems (2nd Edition), 2018-2030

  • $ 3499
  • Industry report
  • June 2018
  • by Roots Analysis Private Ltd.

INTRODUCTIONBiologics constitute a majority of the top selling drugs of today and also represent one of the fastest growing segments of the overall pharmaceutical industry. In fact, the share of biologics ...

Insulin Resistance R&D Pipeline Analysis Report, H2-2018

Insulin Resistance R&D Pipeline Analysis Report, H2-2018

  • $ 2200
  • Industry report
  • August 2018
  • by VPAResearch

Comprehensive Pipeline Review on Ongoing Clinical and Pre-clinical studiesInsulin Resistance Drug Development Pipeline Study is the latest publication from VPA Research with comprehensive information of ...


Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on